Analysts Issue Forecasts for CMPX Q1 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for Compass Therapeutics in a research report issued to clients and investors on Thursday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.09) per share for the quarter. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.11) EPS.

A number of other brokerages have also recently commented on CMPX. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “overweight” rating for the company. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday. Leerink Partners upgraded Compass Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 26th. Citizens Jmp set a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. Finally, Raymond James Financial reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $5.51 on Friday. The stock has a market capitalization of $980.01 million, a PE ratio of -12.81 and a beta of 1.48. The company’s fifty day moving average is $5.90 and its 200 day moving average is $4.79. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CMPX. Russell Investments Group Ltd. grew its holdings in shares of Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Creative Planning bought a new stake in Compass Therapeutics during the 2nd quarter valued at about $30,000. Flagship Harbor Advisors LLC bought a new stake in Compass Therapeutics during the 4th quarter valued at about $32,000. Strs Ohio purchased a new stake in Compass Therapeutics in the 1st quarter valued at about $34,000. Finally, Apollon Wealth Management LLC bought a new position in Compass Therapeutics in the 3rd quarter worth about $35,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics News Summary

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Phase 2/3 COMPANION‑002 tovecimig trial hit the prespecified event threshold (≈80% OS events), so prespecified PFS and OS analyses are expected to be reported in April — a near-term binary clinical readout that could materially move the stock. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Management opened expansion cohorts for CTX‑8371 in TNBC and NSCLC and will add a Hodgkin lymphoma cohort after an additional response — further clinical activity and potential signals that can drive upside. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Q4 results: CMPX reported ($0.09) EPS, beating the consensus ($0.10) loss by $0.01 — a small beat that can be supportive for sentiment. View Press Release
• Neutral Sentiment: HC Wainwright published 2026 quarterly EPS forecasts (Q1: ‑$0.09, Q2: ‑$0.10, Q3: ‑$0.10, Q4: ‑$0.11) and a full‑year loss estimate of ‑$0.36 — these reinforce expectations for continued operating losses but are broadly in line with prior guidance. MarketBeat CMPX
• Negative Sentiment: Reports indicate a “large increase” in short interest in early March, but the published figures show 0 shares and NaN changes (data appears inconsistent). If short interest is actually rising, that would be a bearish signal; the current reporting ambiguity may add volatility. MarketBeat CMPX

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.